TARSUS PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
TARSUS PHARMACEUTICALS, INC. (TARS) reported Defined Contribution Plan, Cost of $3.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-23
- TARSUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2025 was $3.70M, a 68.18% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2024 was $2.20M, a 100.00% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2023 was $1.10M, a 120.00% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2022 was $500.00K.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $3.70M 10-K · filed 2026-02-23 |
| 2024-12-31 | $2.20M 10-K · filed 2026-02-23 |
| 2023-12-31 | $1.10M 10-K · filed 2026-02-23 |
| 2022-12-31 | $500.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |